Appili Therapeutics Appoints Seasoned Biotech Executive Ian C. Mortimer to its Board

HALIFAX, Nova Scotia, November 28, 2018 – Appili Therapeutics Inc. (the “Company” or “Appili”), an anti-infective drug development company, is pleased to announce the appointment of Ian C. Mortimer to its Board of Directors. Mr. Mortimer is a seasoned biotechnology executive with proven abilities in leading capital market transactions. He will serve as chair of Appili’s audit committee.

“Mr. Mortimer is a leader in understanding complex business issues relevant to supporting the growth of life science companies,” said Kimberly Stephens, CFO of Appili Therapeutics. “His expertise is a welcomed addition to our Board as we expand and advance our pipeline of anti-infectives and continue to build shareholder value.”

“Ian brings significant financial acumen onto our Board and we look forward to leveraging his industry experience as Appili advances its cutting-edge anti-infective therapeutics,” said Stephen Nicolle, Appili Therapeutics Board director and president of Cape Bear Advisors. “His acceptance of this role is a testament to the market potential of Appili’s pipeline and to the strength of the leadership we have assembled via the management and Board.”

Mr. Mortimer has over 20 years of experience in the biotechnology sector. He is currently Chief Financial Officer and Chief Operating Officer of Xenon Pharmaceuticals Inc. (NASDAQ: XENE), a company developing medicines to treat neurological disorders. Prior to joining Xenon in 2013, Mr. Mortimer spent six years at Tekmira Pharmaceuticals, now Arbutus Biopharma Corporation (NASDAQ: ABUS), as Executive Vice President and Chief Financial Officer. He is accredited with leading both Xenon’s and Tekmira’s listings on the NASDAQ, in 2014 and 2010 respectively. Mr. Mortimer has an M.B.A. from Queen’s University, a B.Sc. in Microbiology from the University of British Columbia, and is a Chartered Professional Accountant, Certified Management Accountant.

“I am pleased to join Appili’s Board at this pivotal time in the company’s development as the team prepares to take its first antibiotic candidate into clinical trials,” said Mr. Mortimer. “I look forward to contributing to Appili’s future growth in advancing novel treatments to address the growing threat of anti-microbial resistance and other public health challenges caused by infectious diseases.”


About Appili Therapeutics

Appili is dedicated to identifying, acquiring and advancing novel therapeutics for infectious disease. The company has two anti-infective programs, ATI-1501 and ATI-1503, in its pipeline. ATI-1501 is a taste-masked treatment for anaerobic infections, including C. difficile. Appili’s second product, ATI-1503, is a novel antibiotic with broad potential to treat drug-resistant Gram-negative infections. For more information visit